Response To Comments Article

Response to Comments: Oxygen and Oxygen Equipment - DL33797

A58247

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
CGS Administrators, LLC	DME MAC	17013 - DME MAC	J-B	Illinois Indiana Kentucky Michigan Minnesota Ohio Wisconsin
CGS Administrators, LLC	DME MAC	18003 - DME MAC	J-C	Alabama Arkansas Colorado Florida Georgia Louisiana Mississippi New Mexico North Carolina Oklahoma Puerto Rico South Carolina Tennessee Texas Virgin Islands Virginia West Virginia
Noridian Healthcare Solutions, LLC	DME MAC	16013 - DME MAC	J-A	Connecticut Delaware District of Columbia Maine Maryland Massachusetts New Hampshire New Jersey New York - Entire State Pennsylvania Rhode Island Vermont
Noridian Healthcare Solutions, LLC	DME MAC	19003 - DME MAC	J-D	Alaska American Samoa Arizona California - Entire State Guam Hawaii Idaho Iowa Kansas Missouri - Entire State Montana Nebraska Nevada North Dakota Northern Mariana Islands Oregon South Dakota Utah Washington Wyoming

Article Information

General Information

Article ID
A58247

Article Title
Response to Comments: Oxygen and Oxygen Equipment - DL33797

Article Type
Response to Comments

Original Effective Date
06/18/2020

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

During the 45-day comment period, which ended on 02/10/2020, the DME MACs received a total of sixty-five comments. Similar comments were grouped together, resulting in twenty-three unique comments and responses.

Introduction to Responses

The DME MACs appreciate the comments received from stakeholders during the open comment period on the proposed Oxygen and Oxygen Equipment Local Coverage Determination (DL33797).

Pursuant to the CMS Program Integrity Manual (CMS Pub. 100-08) Chapter 13, §§13.2.3 and 13.5.3:

Acceptance by individual health care providers, or even a limited group of health care providers, does not indicate general acceptance of the item or service by the medical community.

In conducting a review, MACs shall use the available evidence of general acceptance by the medical community, such as published original research in peer-reviewed medical journals, systematic reviews and meta-analyses, evidence-based consensus statements and clinical guidelines.

Accordingly, the final policy and our response to comments are based on the best currently available published clinical evidence, to support optimal health outcomes in Medicare beneficiaries with chronic wounds.

Response To Comments

Number	Comment	Response
1	One clinical association requested a change in language in DL33797 from “treating physician” to “treating practitioner.”	The final LCD is reflective of this request.
2	Several commenters, including one clinical association wondered about the composition (lack of a podiatrist on the panel) and overall capabilities of the Contract Advisory Committee (CAC).	All relevant stakeholders, and clinical organizations/associations were invited to nominate candidates for the CAC, and the majority chose not to do so. The CAC panel was comprised of distinguished clinicians and investigators with extensive experience in critically reviewing the clinical literature.
3	Several commenters, including two authors of publications listed in the bibliography (one of whom also wrote a second letter on behalf of a clinical association) felt that several of the Randomized Controlled Trials (RCTs) listed in the bibliography met all the elements in strength and design that CMS required of a “gold standard” study.	CMS has made note of study design and methodological attributes that are usually associated with stronger, higher quality evidence; however, study design is but one input when assessing how much weight to assign to the results of a trial. Even a well-designed RCT might still have other weaknesses that lower the overall strength of the evidence. For example, the sample size (n) of an RCT is an important variable, since the variation of the mean is inversely proportional to the sample size. In other words, when the n is low, there is an increased likelihood that another trial of the same size (or larger) by the same investigators may yield different results. Thus, the weight attributed to an RCT may be lower than expected due to the number of subjects in the active arm of the study, particularly if insufficiently powered. Baseline patient heterogeneity between arms that may affect wound healing, standards of wound care, statistical tools used for analysis of the results, and applicability to the Medicare population are some of the other inputs that are also considered when weighing the results of a study. Of note, applicability to the Medicare population is not only an age criterion, but also reflective of the typical co-morbidities of Medicare beneficiaries, which would have excluded them from participating in some of the trials due to the exclusion criteria(s). Section 13.2.3 of Chapter 13 of the Program Integrity Manual notes: “Acceptance by individual health care providers, or even a limited group of health care providers, does not indicate general acceptance of the item or service by the medical community.” Thus, well-designed RCTs inform, but by themselves are not reflective of general acceptance by the medical community.
4	Several commenters felt that the DME MACs should have independently evaluated the different modalities of oxygen delivery, and their effects on different types of wounds. Two broad subcategories to this group of comments are noted below. Each mode of oxygen delivery was championed by individual commenters who thought that their favored modality was superior to the others in terms of wound healing or quality of life measures and thus, should be selected for separate coverage. Several commenters also felt that specific wound types (for example diabetic foot ulcers) should be covered, instead of a blanket not reasonable and necessary determination.	As noted by one commenter, National Coverage Determinations (NCDs) and LCDs routinely consider specific subtypes of populations and/or conditions for coverage when applicable. The DME MACs did independently consider the different modes of oxygen delivery and wound types during the drafting of DL33797. The rationale in DL33797 includes an independent assessment of recent studies that utilized different modes of oxygen delivery, and that assessment was further categorized by wound types. Although all the studies in the bibliography were not summarized in the rationale due to space limitations, all were independently evaluated. Thus, the final policy determination is reflective of the independent assessments of the entire body of literature noted in the bibliography. Our response to comment # 3 above is reflective of an independent assessment of recent RCTs involving diabetic foot ulcers, and the subsequent policy determinations regarding coverage.
5	Several commenters felt that the external assessments did not include the latest publications, and furthermore were not available to the general public. Several commenters also felt that the evidence analysis was incomplete and thus inaccurate because the DME MACs did not consider all of the latest publications, such as the Frykberg RCT.	The distribution of external assessments is contractually bounded. All external assessments are available for purchase at www.ecri.org. However, we would like to note that the external assessments utilized the same peer-reviewed literature included in the bibliography of DL33797, and thus, the source materials are all publicly available. The DME MACs do not rely solely on external assessments during the policy making process. External assessments are but one input – they inform but are not dispositive in the policy making process. The DME MACs and the CAC independently reviewed the peer-reviewed publications, including the Frykberg RCT on diabetic foot ulcers, which is the first publication listed in the bibliography of DL33797. Finally, as noted in our response to comment #3 above, RCTs inform, but by themselves are not reflective of general acceptance by the medical community.
6	Several commenters discussed their personal experiences with Topical Oxygen Treatment (TOT) used for the treatment of non-healing wounds.	The DME MAC Medical Directors would like to thank patients, Medicare beneficiaries, and practitioners for sharing their stories and clinical experiences. However, when determining if a treatment is “reasonable and necessary” for purposes of Medicare reimbursement, CMS instructs the DME MACs to rely on published peer-reviewed clinical literature, clinical guidelines, consensus documents, etc. (see CMS Program Integrity Manual (PIM), Chapter 13).
7	Several commenters suggested that the CAC meeting did not adhere to the instructions in Chapter 13 of the PIM.	The CAC meeting met all the required elements noted in Chapter 13, Section 13.2.4.3 of the PIM.
8	Several commenters thought that the CAC focused on a “flawed” 2017 CMS Decision Memo and did not adequately discuss some of the more recent publications listed in the bibliography.	The DME MACs neither dictate nor control what CAC members may choose to focus on in their deliberations. The CAC deliberations were informed by the Key Questions, and all CAC members received the clinical literature referenced in DL33797, which included the latest publications.
9	Several commenters disagreed with the assessment of the level of evidence.	Policies are usually grounded on a body of literature. Thus, although certain studies were independently rated as “moderate”, the overall quality of the body of evidence was low, since the overall assessment was derived from the peer-reviewed publications listed in the bibliography.
10	Several commenters thought that the DME MACs focused on a “flawed” 2017 CMS Decision Memo and did not adequately discuss some of the more recent publications listed in the bibliography.	While DL33797 does refer to the 2017 CMS Decision Memo, the DME MACs performed an independent assessment of the clinical evidence, including studies that appeared subsequent to the publication of the CMS Memo, as required by Chapter 13 of the PIM.
11	Several commenters thought that substantial real-world clinical evidence, some published in retrospective studies, and other observational studies demonstrated that topical oxygen was efficacious in the treatment of chronic wounds.	As noted in several recent editorials in the New England Journal of Medicine and the British Medical Journal, all evidence, including RCTs is “real-world” evidence. Retrospective and observational non-randomized studies may be useful, but are generally regarded to be of lower quality, because the lack of randomization does not allow for the control of “known” and “unknown” biases. Thus, when available, prospective RCTs are generally acknowledged to offer higher quality evidence.
12	Several commenters indicated that the products should be covered since they are FDA-approved.	FDA approval is a necessary but insufficient condition for the determination that an item is “reasonable and necessary” for purposes of Medicare reimbursement.
13	Several commenters noted that topical oxygen is covered by the VA, some State Medicaid programs, and by some private insurers - and thus, should also be covered by Medicare.	Coverage determinations by commercial payers and other non-Medicare entities are informative, but not dispositive, for the purposes of Medicare determinations of what is “reasonable and necessary.”
14	Several commenters indicated that in their clinical experience, TOT was superior and cost-effective when compared to Hyperbaric Oxygen Therapy (HBOT) for the treatment of diabetic foot ulcers.	The DME MACs thank the wound care providers for sharing their experience with HBOT versus TOT in their clinical practices. However, the commenters did not submit any peer-reviewed clinical literature to support these observations.
15	Several commenters indicated that the several of the peer-reviewed publications should not have been included in the analysis.	Policies are usually grounded on a body of literature. The overall assessment was derived from the peer-reviewed publications listed in the bibliography.
16	Several commenters requested a delay in finalizing DL33797 noting that a large-scale (>100 enrollees, with >50% Medicare-age), multicenter, prospective randomized controlled trial (“RCT”) evaluating the use of a new TOT system in treating diabetic wounds is well underway and is expected to be completed and published within this LCD reconsideration timeline.	Chapter 13 of the PIM enumerates the LCD reconsideration request timelines. Thus, the DME MACs do not have the discretion to change those timelines. Unlike the FDA approval process where one pivotal study may result in approval of a drug or device, the DME MACs consider a broader body of evidence and general acceptance during the policy making process.
17	Several commenters noted the Driver et al. studies should not be included in the analysis as the technology investigated in those trials was disposable and did not meet the definition of DME.	The DME MACs thank the commenters for pointing out that the device used in these studies was disposable. However, the DME MACs review of the literature, including the CAC Key Questions, was geared towards an evidentiary assessment of the effectiveness and general acceptance of topical oxygen for the treatment of chronic wounds. Thus, the publications by Driver et. al. were germane to our assessment.
18	Several commenters felt that some clinical guideline recommendations may have been influenced by potential financial conflicts of interest.	The DME MACs rely on the clinical organizations to monitor and mitigate the risk of conflicts of interest with their guidelines. The DME MACs note that clinical guidelines are but one input – they inform but are not dispositive in the policy making process.
19	Several commenters questioned why studies from Bowen et. al. and Lavery et. al. were not referenced in the proposed LCD.	The 2019 publication by Lavery et. al. is included in the bibliography and was considered. The publication by Bowen et. al. was not published in a peer-reviewed journal as required in Chapter 13, Section 13.5.3 of the PIM, and was thus not considered.
20	Several commenters questioned if NPWT or HBO would be a covered benefit if given the same level of scrutiny as TOT.	A comparative evidentiary assessment of other NCDs and LCDs is outside the scope of this reconsideration request.
21	Several commenters indicated the draft LCD does not accurately incorporate the outcomes from the most recent AOTI RCT in DFUs that was published in Diabetes Care on 10/16/19 after the reconsideration process had commenced.	Please see our response to comments # 3, 4 and 5 above. The DME MAC Medical Directors fully analyzed all outcomes published in the AOTI RCT in DFUs.
22	One commenter was concerned that the CAC process for TOT was conducted very differently than the Tumor Treatment Field Therapy (TTFT) CAC process (DL34823). They Specifically noted concerns included member selection, manufacturer involvement, the length of meeting, and location.	As noted in our response to comment #7 above, the CAC meeting met all the required elements noted in Section 13.2.4.3 of Chapter 13 of the Program Integrity Manual (PIM). The PIM is not proscriptive regarding any of the concerns expressed by the commenter.
23	Several commenters noted that TOT is safer than other wound treatment therapies, such as NPWT.	Safety is the purview of the Food and Drug Administration, and the DME MACs only review items that have received FDA approval.

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
LCDs
L33797 - Oxygen and Oxygen Equipment

Updated On	Effective Dates	Status
06/12/2020	06/18/2020 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: Oxygen and Oxygen Equipment - DL33797

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: Oxygen and Oxygen Equipment - DL33797 (A58247)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS